Japanese Billionaire Masayoshi Son’s Investments: Top 5 Stock Picks

2. AbCellera Biologics Inc. (NASDAQ:ABCL)

SB Management’s holdings: $196 million

Percentage of SB Management’s Portfolio: 20.15%

Number of Hedge Fund Holders: 21

AbCellera Biologics Inc. (NASDAQ:ABCL) runs an artificial intelligence (AI) powered database of data from human immune systems. It utilizes this database to discover antibodies for drug development. It was founded in 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc. (NASDAQ:ABCL) reported $5.51 million in revenue and a GAAP EPS of -$0.08 in its Q3 as it missed analyst estimates for both metrics. Piper Sandler set a $33 price target for the company in a November 2021 analyst note which claimed that AbCellera Biologics Inc. (NASDAQ:ABCL) can become the industry leader for antibody drug discoveries because of its technologies.

Mr. Son’s SB Management held 9.8 million AbCellera Biologics Inc. (NASDAQ:ABCL) shares during Q3 2021. These were worth $196 million and represented 20.15% of the firm’s portfolio. In the third quarter of 2021, out of the 867 hedge funds surveyed by Insider Monkey, 21 held a stake in the company.

AbCellera Biologics Inc. (NASDAQ:ABCL)’s largest shareholder is Julian Baker and Felix Baker’s Baker Bros. Advisors which holds 10.4 million shares worth $209 million.